EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Gut-bone axis: mechanisms and intervention effects of Chinese botanical drugs in osteoporosis management

Shiyu Li, Hongyu Liu

Frontiers in Pharmacology · 17.06.2026 · 17

DOI: 10.3389/fphar.2026.1842067 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 17.06.2026. Verfasst von Shiyu Li und 1 weiteren Autor:innen. Beteiligte Einrichtung: Rehabilitation Department, Central Hospital of Dalian University of Technology, Dalian Municipal Central Hospital, Dalian, Liaoning, China. Die Arbeit nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Osteoporosis (OP) is a systemic skeletal disorder characterized by decreased bone mass, impaired bone microarchitecture, and elevated fracture risk. With global population aging, OP has become a major public health burden worldwide. The gut-bone axis, a critical regulatory network connecting gut microbiota (GM) and bone metabolism, has emerged as a frontier in OP pathogenesis and intervention. GM dysbiosis disrupts bone homeostasis through metabolic, endocrine, and immune pathways, including short-chain fatty acids, estrogen/parathyroid hormone signaling, and Th17/Treg balance. Chinese botanical drugs (CBDs) exert unique advantages in OP management via holistic and multi-target effects, particularly by regulating GM to restore gut-bone axis balance. This review systematically elaborates the mechanisms by which GM contributes to OP, and summarizes advances in CBDs that regulate bone metabolism by remodeling GM composition, improving intestinal barrier function, and modulating gut-bone axis signaling. This work provides theoretical support for the clinical application and innovative research of CBDs, and lays a foundation for developing novel GM-targeted anti-OP therapeutic strategies.

Schlagwörter

Stichwörter der Autor:innen

Chinese botanical drugbone homeostasisgut microbiotagut-bone axisosteoporosis

Autor:innen und Institutionen

  • Rehabilitation Department, Central Hospital of Dalian University of Technology, Dalian Municipal Central Hospital, Dalian, Liaoning, China.
  • Department of Pharmacy, Central Hospital of Guangdong Prison, Guangzhou, Guangdong, China.

Zitieren

APA

Li, S., & Liu, H. (2026). Gut-bone axis: mechanisms and intervention effects of Chinese botanical drugs in osteoporosis management. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1842067

Vancouver

Li S, Liu H. Gut-bone axis: mechanisms and intervention effects of Chinese botanical drugs in osteoporosis management. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1842067

BibTeX
@article{Li2026,
  author = {Li, Shiyu and Liu, Hongyu},
  title = {Gut-bone axis: mechanisms and intervention effects of Chinese botanical drugs in osteoporosis management},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1842067}
}
Kostenlos starten →